Charles River Laboratories International (CRL) closed at $351.87 on November 3, 2026, up 3.9% from the previous close, on volume of 1,447,267 shares (30-day average 1,093,452).
Data as of November 3, 2026.
Market Chameleon (Wed, 4-Nov 4:02 AM ET)
Charles River Laboratories beats top-line and bottom-line estimates; updates FY26 outlook
Seeking Alpha News (Wed, 4-Nov 7:16 AM ET)
Charles River Laboratories Announces Third-Quarter 2026 Results
Business Wire (Wed, 4-Nov 7:00 AM ET)
Here are the major earnings before the open Wednesday
Seeking Alpha News (Tue, 3-Nov 6:00 PM ET)
Charles River Laboratories Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 11:09 AM ET)
Healthcare sector rallies in October amid rotation away from technology stocks
Seeking Alpha News (Sat, 31-Oct 11:05 AM ET)
Charles River Leverages Virtual Control Groups in GLP Studies
Business Wire (Tue, 27-Oct 8:00 AM ET)
Business Wire (Thu, 22-Oct 4:30 PM ET)
Business Wire (Tue, 13-Oct 8:00 AM ET)
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Business Wire (Fri, 9-Oct 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of November 4, 2026, CRL stock price declined to $331.55 with 818,941 million shares trading.
CRL has a beta of 1.35, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.11 to the broad based SPY ETF.
CRL has a market cap of $16.95 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $3.02 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.29.
In the last 3 years, CRL traded as high as $379.63 and as low as $91.86.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
CRL has outperformed the market in the last year with a price return of +85.4% while the SPY ETF gained +13.6%. CRL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.6% and +5.1%, respectively, while the SPY returned +1.7% and -0.1%, respectively.
CRL support price is $340.60 and resistance is $363.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.